Clinical trials: Heart Failure With Normal Ejection Fraction
- Condition Heart Failure With Normal Ejection Fraction
- Funder type Industry (pharma, biotech, devices)
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Chronic Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction
Main objective: To evaluate the efficacy, safety and clinical dose exploration of Qishen Yiqi dripping pills in the treatment of chronic heart failure with preserved ejection fraction.
- Trial name
- NCT04944706
- Testing
- Qishen Yiqi dripping pills 4 bags/time
- Where
- 16 sites in China
- Volunteers
- 225 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Heart Failure With Preserved Ejection Fraction (HFpEF)
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
The effect of sacubitril/valsartan vs. valsartan on changes in NT-proBNP, safety, and tolerability in HFpEF patients with a WHF event (HFpEF decompensation) who had been stabilized and initiated at the time of or within 30 days…
- Trial name
- PARAGLIDE-HF (NCT03988634)
- Testing
- sacubitril/valsartan, valsartan
- Where
- 97 sites in United States, Canada
- Volunteers
- 467 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Preserved Ejection Fraction
Evaluation of Rate Adaptive Pacing on Chronotropic Response in Preserved Ejection Fraction HF
RESPOND-HF is a prospective, multi-center, non-significant risk pilot study with cross-over design. The purpose of the study is to investigate if rate adaptive pacing has the potential to provide benefit to HF patients with…
- Trial name
- RESPOND-HF (NCT03160625)
- Testing
- Rate Adaptive Pacing
- Where
- 5 sites in United States
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure With Normal Ejection Fraction, Sleep Apnea
Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
This study is designed to demonstrate feasibility of study conduct and that acceptable adherence to adaptive servo-ventilation (ASV) therapy can be achieved in recently hospitalized HFpEF patients with moderate to severe sleep…
- Trial name
- CAT-PEF (NCT03195660)
- Testing
- ASV Therapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 6 people
- Sponsor
- ResMed
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment for heart…
- Trial name
- NCT01951638
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 158 sites in United States, Australia and 23 more
- Volunteers
- 477 people
- Sponsor
- Bayer
Heart Failure With Preserved Ejection Fraction (HFpEF)
ELEVATE-HFpEF Clinical Study
ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing…
- Trial name
- ELEVATE-HFpEF (NCT06678841)
- Testing
- Personalized cardiac pacing
- Where
- 51 sites in United States, Australia and 13 more
- Volunteers
- 700 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Cardiopulmonary Failure, Myocardial Infarction (MI)
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
The COR-INSIGHT trial aims to evaluate the effectiveness of Peerbridge COR advanced ambulatory ECG wearables (COR 1.0 and COR 2.0) in accurately and non-invasively detecting cardiovascular and cardiopulmonary conditions using…
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure
- Trial name
- COR-INSIGHT (NCT06763549)
- Testing
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Transthyretin Amyloidosis Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia
A multicenter observational retrospective-prospective study of prevalence and clinical characteristics of transthyretin amyloidosis (ATTR) cardiomyopathy (CM) in Russian patients with heart failure with preserved ejection…
- Trial name
- TETRAMER (NCT06338839)
- Where
- 21 sites in Russia
- Volunteers
- 1,770 people
- Sponsor
- AstraZeneca
Diastolic Heart Failure
Ranolazine in Diastolic Heart Failure
Patients with CAD and clinical symptoms of heart failure or patients with suspected heart failure with preserved ejection fraction (HFpEF) will be enrolled.
- Trial name
- RALI-DHF (NCT01163734)
- Testing
- Ranolazine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Heart Failure
Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium
This is a Phase I, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium [sK+] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range of ≥40 and ≤70 mL/min/1.73m2.
- Trial name
- NCT03682497
- Testing
- AZD9977, Spironolactone
- Where
- 18 sites in Bulgaria, Czechia and 2 more
- Volunteers
- 68 people
- Sponsor
- AstraZeneca
Heart Failure
Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
A randomized, double-blind, placebo-controlled, parallel group, multicentre study in patients with Heart Failure with preserved Ejection Fraction (HFpEF). The study will be conducted at approximately 15 sites in 5 countries.
- Trial name
- SATELLITE (NCT03756285)
- Testing
- AZD4831
- Where
- 13 sites in United States, Denmark and 3 more
- Volunteers
- 41 people
- Sponsor
- AstraZeneca
Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF)
Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program
This observational cohort study evaluates temporal trends and determinants of sodium-glucose cotransporter 2 inhibitor (SGLT2i) prescriptions among adults with chronic heart failure enrolled in a nationwide remote monitoring…
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Reduced Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Trial name
- REMOTE-HF (NCT07022379)
- Testing
- SGLT2 Inhibitor Use
- Where
- France
- Volunteers
- 13,660 people
- Sponsor
- Satelia
Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
The aim of this open-label (OL) extension trial is to study the long-term safety and efficacy of macitentan in subjects with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease (PVD) beyond the…
- Trial name
- SERENADE OL (NCT03714815)
- Testing
- macitentan 10 mg
- Where
- 44 sites in United States, Argentina and 13 more
- Volunteers
- 91 people
- Sponsor
- Actelion
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Extended IASD Investigation: REDUCE LAP-HF IV
Multicenter, Prospective, Open Label, Single Arm, Clinical Trial. The primary objective of this clinical trial is to further evaluate the safety and clinical efficacy of the IASD System II in symptomatic heart failure patients…
- Trial name
- NCT04632160
- Testing
- IASD System II
- Sponsor
- Corvia Medical